author-photo

Philip C. Mack

University of California, Davis

219

Papers

6383

Citations

Citation Trend

Filter By

Papers (219) Sort By

Journal Conference Others

Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer: The Lung-MAP S1400I Phase 3 Randomized Clinical Trial.

2021 JAMA Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Phase I/II Study of Capmatinib Plus Erlotinib in Patients With MET-Positive Non–Small-Cell Lung Cancer

2021
Show All
- Source
- Cite
- Save
Citations (1)
EGFR High Copy Number Together With High EGFR Protein Expression Predicts Improved Outcome for Cetuximab-based Therapy in Squamous Cell Lung Cancer: Analysis From SWOG S0819, a Phase III Trial of Chemotherapy With or Without Cetuximab in Advanced NSCLC.

2021 Clinical Lung Cancer
Show All
- Source
- Cite
- Save
Citations (0)
A Phase II Study of Talazoparib in Patients with Homologous Recombination Repair Deficient Squamous Cell Lung Cancer (Lung-MAP Sub-Study S1400G)

2021 Clinical Lung Cancer
Show All
- Source
- Cite
- Save
Citations (3)
Erlotinib and Onalespib Lactate Focused on EGFR Exon 20 Insertion Non-Small Cell Lung Cancer (NSCLC): A California Cancer Consortium Phase I/II Trial (NCI 9878)

2021 Clinical Lung Cancer
Show All
- Source
- Cite
- Save
Citations (1)
Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in non–small cell lung cancer: Analysis of over 8000 cases

2020 Cancer
Show All
- Source
- Cite
- Save
Citations (28)
Ethnic difference in lung cancer: an important issue in a globalized society

2020 Journal of Thoracic Disease
- Tomoya Kawaguchi
- Philip C. Mack
Show All
- Source
- Cite
- Save
Citations (2)
Novel Synergistic Combination of Mitotic Arrest and Promotion of Apoptosis for Treatment of Pancreatic Adenocarcinoma.

2019 Translational Oncology
Show All
- Source
- Cite
- Save
Citations (7)
Randomized Phase 2 Study of Trebananib (AMG 386) with or without Continued Anti-Vascular Endothelial Growth Factor Therapy in Patients with Renal Cell Carcinoma Who Have Progressed on Bevacizumab, Pazopanib, Sorafenib, or Sunitinib – Results of NCI/CTEP Protocol 9048

2019
Show All
- Source
- Cite
- Save
Citations (4)
A phase II study of talazoparib (BMN 673) in patients with homologous recombination repair deficiency (HRRD) positive stage IV squamous cell lung cancer (Lung-MAP Sub-Study, S1400G).

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (6)